Literature DB >> 8640994

Relation between activated clotting time during angioplasty and abrupt closure.

C R Narins1, W B Hillegass, C L Nelson, J E Tcheng, R A Harrington, H R Phillips, R S Stack, R M Califf.   

Abstract

BACKGROUND: The purpose of this study was to determine whether the degree of heparin anticoagulation during coronary angioplasty, as measured by the activated clotting time, is related to the risk of abrupt vessel closure. METHODS AND
RESULTS: Sixty-two cases of in- and out-of-laboratory abrupt closure in patients in whom intraprocedure activated clotting times were measured were identified from a population of 1290 consecutive patients who underwent non-emergency coronary angioplasty. This group was compared with a matched control population of 124 patients who did not experience abrupt closure. Relative to the control population, patients who experienced abrupt closure had significantly lower initial (median, 350 seconds [25th to 75th percentile, 309 to 401 seconds] versus 380 seconds [335 to 423 seconds], P = .004) and minimum (345 seconds [287 to 387 seconds] versus 370 seconds [321 to 417 seconds], P = .014) activated clotting times. Higher activated clotting times were not associated with an increased likelihood of major bleeding complications. Within this population, a strong inverse linear relation existed between the activated clotting time and the probability of abrupt closure.
CONCLUSIONS: This study demonstrates a significant inverse relation between the degree of anticoagulation during angioplasty and the risk of abrupt closure. A minimum target activated clotting time could not be identified; rather, the higher the intensity of anticoagulation, the lower the risk of abrupt closure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640994     DOI: 10.1161/01.cir.93.4.667

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

2.  In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Authors:  A J Peters; M Borries; F Gradaus; T W Jax; F C Schoebel; B E Strauer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

3.  Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

Authors:  S Tsimikas; R Beyer; A Hassankhani
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

4.  Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.

Authors:  R Kubalek; A Berlis; M Schwab; J Klisch; M Schumacher
Journal:  Neuroradiology       Date:  2003-03-28       Impact factor: 2.804

5.  Safety of low dose heparin in elective coronary angioplasty.

Authors:  K T Koch; J J Piek; R J de Winter; G K David; K Mulder; J G Tijssen; K I Lie
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 6.  A guide to drug use during percutaneous coronary intervention.

Authors:  Joseph K Choo; John J Young; Dean J Kereiakes
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Anticoagulation in neurointerventions: basic pharmacology and pathophysiology, current status, practical advice.

Authors:  J Scharf; C-E Dempfle
Journal:  Clin Neuroradiol       Date:  2012-02-07       Impact factor: 3.649

Review 8.  Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.

Authors:  H M Hussein; A L Georgiadis; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-15       Impact factor: 3.825

Review 9.  Heparin dose during percutaneous coronary intervention: how low dare we go?

Authors:  G Niccoli; A P Banning
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

10.  A Nanoscale Tool for Photoacoustic-Based Measurements of Clotting Time and Therapeutic Drug Monitoring of Heparin.

Authors:  Junxin Wang; Fang Chen; Santiago J Arconada-Alvarez; James Hartanto; Li-Peng Yap; Ryan Park; Fang Wang; Ivetta Vorobyova; Grant Dagliyan; Peter S Conti; Jesse V Jokerst
Journal:  Nano Lett       Date:  2016-09-28       Impact factor: 11.189

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.